TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis

Abstract

Introduction

Recent discoveries have identified shortened telomeres and related mutations in people with pulmonary fibrosis (PF). There is evidence to suggest that androgens, including danazol, may be effective in lengthening telomeres in peripheral blood cells. This study aims to assess the safety and efficacy of danazol in adults and children with PF associated with telomere shortening.

Methods and analysis

A multi-centre, double-blind, placebo-controlled, randomised trial of danazol will be conducted in subjects aged >5 years with PF associated with age-adjusted telomere length ≤10th centile measured by flow fluorescence in situ hybridisation; or in children, a diagnosis of dyskeratosis congenita. Adult participants will receive danazol 800 mg daily in two divided doses or identical placebo capsules orally for 12 months, in addition to standard of care (including pirfenidone or nintedanib). Paediatric participants will receive danazol 2 mg/kg/day orally in two divided doses or identical placebo for 6 months. If no side effects are encountered, the dose will be escalated to 4 mg/kg/day (maximum 800 mg daily) orally in two divided doses for a further 6 months. The primary outcome is change in absolute telomere length in base pairs, measured using the telomere shortest length assay (TeSLA), at 12 months in the intention to treat population.

Ethics and dissemination

Ethics approval has been granted in Australia by the Metro South Human Research Ethics Committee (HREC/2020/QMS/66385). The study will be conducted and reported according to Standard Protocol Items: Recommendations for Interventional Trials guidelines. Results will be published in peer-reviewed journals and presented at international and national conferences.

Trial registration numbers

NCT04638517; Australian New Zealand Clinical Trials Registry (ACTRN12620001363976p).

Correspondence to Dr John A Mackintosh; [email protected]

Introduction

Progressive pulmonary fibrosis (PF) is a relatively rare condition that leads to substantial morbidity and mortality. The treatment of progressive PF, particularly in its idiopathic form (IPF), has undergone dramatic change over the last decade. In 2012, a major shift in the management of IPF occurred, with the publication of the Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Reponse in Idiopathic Pulmonary Fibrosis (PANTHER-IPF) trial which demonstrated harm from this combination, which had been the standard of care until that point.¹ Subsequently two agents, nintedanib and pirfenidone, jointly coined antifibrotics, have proved efficacious to slow disease progression, reduce the frequency of acute exacerbation and improve survival.^2–4 However, these medications are not a cure, and do not completely halt disease progression. While they both have demonstrated broad activity across the spectrum of fibrosing interstitial lung diseases,^5–7 their activity targets down-stream pathways of lung fibrosis. Disease modifying therapies in their truest sense, require activity at the very origins of disease pathogenesis.

Recent discoveries have begun to unravel fundamental genetic abnormalities in a significant proportion of patients with PF. The most frequent genetic abnormalities are found in genes involved in telomere maintenance. Telomeres are nucleoprotein complexes consisting of long, TTAGGG repeat segments, which protect chromosomes from loss of genomic material during cell replication. Telomere length is regulated by the enzyme telomerase and shortening occurs naturally with age. Mutations in telomere-maintenance genes cause extreme shortening, and were first recognised to lead to fatal PF in children with dyskeratosis congenita (DC).⁸ Subsequently, similar mutations were identified in adults with PF.⁹ Telomere shortening is frequently identified in adult PF and defines disease behaviour.^{10 11} In IPF, telomere length is directly proportionate to survival—those with the shortest telomere lengths have the worst survival.^12–15 Additionally, post-hoc evaluation of the pivotal PANTHER trial suggests that a proportion of the adverse outcomes with immunosuppression was attributable to the treatment’s impact in patients with short telomeres.¹⁶ In chronic hypersensitivity pneumonitis, the presence of shortened telomeres predicts a survival identical to IPF.¹⁷ Shortened telomeres and their associated genetic mutations (TERT, TERC, RTEL1 and PARN) predict adverse outcomes among families with inherited interstitial lung diseases (ILDs), despite heterogeneous radiology and histology.¹² Finally, the presence of telomere shortening impacts lung transplantation complications and survival, and data are emerging to suggest that such patients should be managed differently in the post-transplantation period.¹⁸

The evidence above suggests that the telomere apparatus is a potential treatment target in PF. Preserving, and potentially elongating telomere length may help to prevent progressive PF. Danazol, a synthetic androgen, has demonstrated potential efficacy in this regard.¹⁹ In 27 subjects with a variety of short telomere related blood disorders, telomeres were lengthened with danazol.¹⁹ Ten participants with PF had stable lung function over 2 years of treatment. A case report from our group demonstrated similar benefit with danazol.²⁰ Moreover, in 17 patients, including 6 with PF, a similar androgen (intramuscular nandrolone) resulted in telomere elongation by 1119 base pairs (bp) at 12 months, and resolution of respiratory failure in 1 patient.²¹ Further support for a potential role of androgens in PF stems from data demonstrating lower testosterone levels in males with IPF, which correlated with shorter telomere length.²² However, previous trials have significant limitations, including missing data, no comparator group, and the majority of participants had extremely short telomeres (less than first centile). Additionally a study in 10 haematology patients failed to confirm an effect of danazol on telomere length.²³ Ongoing studies of androgens highlight the worldwide interest in this therapy for short telomere syndromes. However, these studies either have a haematological (USA, NCT03312400; France, EudraCT 2018-001686-17, South America, NCT02055456) or paediatric (Boston, NCT01001598) focus.

The TELO-SCOPE Study: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial of Danazol for Short Telomere Related Pulmonary Fibrosis, will be the first study to specifically study danazol in PF associated with short telomeres and has been deliberately designed to align with international protocols so that subsequent meta-analyses are facilitated. The primary endpoint of the study is change in telomere length over 12 months of treatment, allowing the study to be adequately powered. We hypothesise that danazol will result in reduced telomere attrition in patients with PF associated with short telomeres.

Methods and analysis

Design

TELO-SCOPE is a national, multi-centre, double-blind, placebo-controlled, randomised trial which will be conducted in subjects aged over 5 years with a multi-disciplinary diagnosis of PF and with age-adjusted telomere length less than or equal to the 10th centile in adults; and for children (aged less than 16 years), a confirmed diagnosis of DC. The study is designed according to Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines, will be conducted in accordance with the principles of Good Clinical Practice and reported according to Consolidated Standards of Reporting Trials standards. The study has been notified to the Therapeutic Goods Administration Australia (CT-2020-CTN-04 759-1).

Participants

Adults and children (aged older than 5 years) with a fibrosing ILD on high-resolution CT (HRCT) who meet all other inclusions with no exclusions are eligible to participate in this trial (box 1). A key inclusion will be the presence of shortened telomeres, defined as age adjusted peripheral blood leucocyte telomere length less than or equal to the 10th centile measured by flow fluorescence in situ hybridisation (flow-FISH). Flow-FISH was chosen for screening purposes as it is the clinically accepted diagnostic test for telomere length.^{24 25} Flow-FISH measures median telomere length in a cell population and allows for a patient’s telomere length to be rapidly referenced to a control population, with telomere lengths below the 10th centile being indicative of underlying telomere related gene mutations.²⁶ Other inclusion criteria are as follows: (1) males and females aged over 5 years, able to take capsules orally; (2) fibrosing interstitial pneumonia (including, but not limited to: IPF, non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, pleuroparenchymal fibroelastosis, unclassifiable ILD) diagnosed according to current international guidelines^{27 28}; (3) forced vital capacity >40% predicted; (4) diffusion capacity for carbon monoxide >25% predicted; (5) if receiving background pirfenidone or nintedanib, stable dose for 28 days prior to screening; (6) able to understand and sign a written informed consent form (or legally authorised representative); (7) agreement to use a medically approved form of non-hormonal contraception (if of childbearing potential) and noting that oral contraceptives are advised not to be used concurrently with danazol.

Box 1

Inclusion and exclusion criteria

Inclusion criteria

• Males and females aged >5 years, able to take capsules orally.

• Fibrosing interstitial pneumonia (including, but not limited to, idiopathic pulmonary fibrosis (PF), non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, pleuroparenchymal fibroelastosis, unclassifiable interstitial lung disease).

• Age-adjusted peripheral blood leucocyte telomere length ≤10th centile on flow fluorescence in situ hybridisation.

• Forced vital capacity >40% predicted.

• Diffusion capacity for carbon monoxide >25% predicted.

• If receiving background pirfenidone/nintedanib, stable dose for 28 days prior to screening.

• Able to understand and sign a written informed consent form (or legally authorised representative).

• Agreement to use a medically approved form of non-hormonal contraception (if of childbearing potential) (noting that oral contraceptives are advised not to be used concurrently with danazol).

Exclusion criteria

• Actively or imminently listed for lung transplantation.

• Undergone, awaiting or likely to require bone marrow transplantation within 12 months.

• Concurrent enrolment in another study.

• Females with a positive pregnancy test at screening or currently breast feeding.

• Pelvic infection.

• Past jaundice with oral contraceptives.

• Undiagnosed abnormal genital bleeding.

• Undiagnosed ovarian/uterine masses.

• Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 12 months.

• History of androgen-dependent tumour.

• Any condition other than PF that, in the opinion of the investigator, is likely to result in the death of the participant within the next 12 months.

• History of end-stage liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal.

• History of end-stage kidney disease requiring dialysis.

• Markedly impaired cardiac function.

• Known increased risk of or history of thromboembolism (eg, Factor V Leiden, protein C or S deficiency).

• Uncontrolled hypertension.

• Uncontrolled lipoprotein disorder.

• Poorly controlled diabetes mellitus.

• History of marked or persistent androgenic reaction to previous gonadal steroid therapy.

• History of epilepsy induced or worsened by previous gonadal steroid therapy.

• History of raised intracranial pressure.

• Known intolerance to danazol.

• Porphyria.

• Use of any of the following agents within 28 days before screening: danazol or other androgen therapy, warfarin or other anticoagulant, carbamazepine, phenytoin, investigational therapy, cytotoxic therapy, tacrolimus, cyclosporine, simvastatin.

• Professional singer due to potential for voice change.

• Competitive athletes.

• Lactose intolerance.

• Prostate specific antigen above the upper limit of normal (adult males only).

Subjects will be excluded if any of the following criteria are present: actively or imminently listed for lung transplantation; undergone, awaiting, or likely to require bone marrow transplantation within 12 months; concurrent enrolment in another study; females with a positive pregnancy test at screening or currently breast feeding; pelvic infection; past jaundice with oral contraceptives; undiagnosed abnormal genital bleeding; undiagnosed ovarian/uterine masses; any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 12 months; history of androgen-dependent tumour; any condition other than PF that, in the opinion of the investigator, is likely to result in the death of the participant within the next 12 months; history of end-stage liver disease or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal; history of end-stage kidney disease requiring dialysis; markedly impaired cardiac function; known increased risk of or history of thromboembolism (eg, factor V Leiden, protein C or S deficiency); uncontrolled hypertension; uncontrolled lipoprotein disorder; poorly controlled diabetes mellitus; history of marked or persistent androgenic reaction to previous gonadal steroid therapy; history of epilepsy induced or worsened by previous gonadal steroid therapy; history of raised intracranial pressure; known intolerance to danazol; porphyria; use of any of the following agents within 28 days before screening: danazol or other androgen therapy, warfarin or other anticoagulant, carbamazepine, phenytoin, investigational therapy, cytotoxic therapy, tacrolimus, cyclosporine, simvastatin; professional singer due to potential for voice change; competitive athletes; lactose intolerance; and prostate specific antigen above the upper limit of normal (adult males only).

The inclusion criteria have been developed in line with those for previously reported studies of antifibrotics in PF and the Townsley et al danazol study.^{2 3 19} The Townsley et al study used a threshold of age-adjusted telomere length less than the first centile.¹⁹ A slightly longer, but still abnormal, telomere length threshold (less than or equal to the 10th centile) has been chosen in this study as it has been demonstrated in multiple studies to be associated with mutations in the telomere-maintenance genes and outcomes in PF,^{9–11 14} and since the treatment effect of danazol was found to be independent of baseline telomere length in the study by Townsley et al.¹⁹

Recruitment

Participants will be recruited from an existing IPF Registry, the investigator’s ILD clinics, and the ILD multi-disciplinary meetings held at all sites. Patients with PF known to be associated with short telomeres or DC will be approached initially. Patients with clinical features suggestive of a short telomere syndrome (eg, young age of onset, a family history of PF, early greying of the hair, haematological abnormalities) will be targeted for recruitment.⁸ If not already enrolled, subjects with age-adjusted telomere length above the 10th centile will be offered enrolment in the Australian ILD Registry so that the impact of telomere length on the natural history of PF can be ascertained.²⁹ Participants will be advised of their telomere length result alongside genetic counselling. All participants with a telomere length less than or equal to the 10th centile will be offered a clinical genetics consultation. Whole genome sequencing will be performed for those individuals with telomere length ≤10th percentile. Known telomere related genes will be screened for pathogenic variants that meet the American College of Medical Genetics and Genomics (ACMG) guidelines for interpretation of sequence variants. Clinically significant findings will be returned to participants following best practice guidelines. Additionally, subjects with positive family histories for ILD, will be offered enrolment in the Genetic Research in Idiopathic Pulmonary Fibrosis study.

Flow-FISH for telomere length screening

For screening, relative (percentile) telomere length will be assessed with flow-FISH, using the peptide nucleic acid (PNA) Kit/FITC for Flow Cytometry (DAKO) according to the manufacturer’s instructions. Peripheral blood mononuclear cells (PBMCs) will be isolated by density gradient separation, within 40 hours of collection, before freezing for further use. Peripheral blood leucocyte telomere length has been used by multiple investigators as a surrogate for telomere related pathology in solid organs, including the lung, in observational^{10 11 13–17} and previous interventional studies.^{19 21} PBMCs washed with phosphate-buffered saline (PBS) will be mixed with the control cell line (1301) and their DNA denatured in a heating block adjusted to 82°C for 10 min in hybridisation solution with or without a fluorescently labelled telomere specific probe. After an overnight incubation at room temperature, samples will be washed and the DNA stained. Finally, samples will be run on a flow cytometer and telomere length estimated by comparison to the control cell line.

Intervention

Adult participants will receive danazol at a dose of 800 mg daily in two divided doses or identical placebo capsules orally for 12 months, in addition to standard of care (eg, pirfenidone or nintedanib). This dose was chosen as it was studied by Townsley et al and was tolerated well over 24 months.¹⁹ In subjects who have difficulty tolerating danazol/placebo, the dose will be reduced by 200 mg/day and side effects will be reassessed. If symptoms related to the study drug persist, subsequent 200 mg/day dose reductions will be allowed until a tolerated dose is achieved. If the subject cannot tolerate danazol/placebo 200 mg/day, the drug will be discontinued. Background antifibrotic therapy is allowed as drug pharmacokinetics do not predict interactions or additive hepatotoxicity, but these will be a key focus of the safety assessments.

Paediatric participants will receive danazol 2 mg/kg/day orally in two divided doses rounded to the nearest 100 mg (maximum 800 mg daily) or identical placebo for the first 6 months of the trial. If no side effects are encountered, the dose will be escalated to 4 mg/kg/day (max 800 mg daily) orally in two divided doses rounded to the nearest 100 mg for a further 6 months.

Randomisation and blinding

Concealed random allocation will be employed using an online randomisation system in a 2:1 fashion generated with permuted blocks of various sizes. Blinding will be achieved by an over-encapsulation method using gelatin capsules. Placebo capsules will be packed with microcrystalline cellulose. Individual participant treatment assignments will not be unblinded during the study unless there is a regulatory obligation, or a patient safety issue arises in which unblinding is necessary to ensure optimal patient management. While the study is ongoing, individual patient unblinding not related to regulatory requirements will only occur after approval from the medical monitor or designee.

Outcome measures

The primary outcome is change in absolute telomere length in base pairs (bp) at 12 months in the intention to treat population. Absolute telomere length (bp) will be measured at baseline, 3, 6, 9 months and end-of-study visits using the telomere shortest length assay (TeSLA). TeSLA was chosen to measure primary outcome because it measures individual telomere lengths, and provides more precise information regarding the abundance, distribution and length of the shortest telomeres.^{25 30} In brief, genomic DNA will be ligated with overhang adaptors, digested with a restriction enzyme panel, and ligated with double-stranded adaptors.²⁵ Ligated telomeric DNA will be amplified using PCR and products resolved by agarose gel electrophoresis. Gels will be dried, denatured, neutralised and subject to in-gel hybridisation with a γ-[32P]-ATP–labelled (CCCTAA)₃ probe in Church buffer. Gels will be washed and exposed to a PhosphorImager screen. Secondary and safety outcome measures, including changes in lung function parameters, are listed in box 2.

Box 2

Secondary and safety outcome measures

Secondary outcome measures

• Treatment-emergent adverse events.

• Treatment-emergent changes in clinical laboratory parameters.

• Treatment-emergent deaths.

• Change in telomere length (bp) at 3, 6 and 9 months.

• Change in forced vital capacity (FVC, mL) at 6 and 12 months.

• Change in FVC (% predicted) at 6 and 12 months.

• Change in diffusing capacity for carbon monoxide (% predicted) at 6 and 12 months.

• Change in 6-minute walk distance (m) at 12 months.

• Change in participant reported outcomes (Leicester Cough, Parent Cough-Specific Quality of Life and King’s Brief Interstitial Lung Disease questionnaires).

• Change in haematological parameters (haemoglobin, platelet count, white cell count).

• Change in telomere length (bp) at 12 months stratified by telomere-maintenance mutation.

• Change in high-resolution CT.

Safety outcome measures

• Treatment-emergent adverse events (AEs).

• Treatment-emergent serious adverse events (SAEs).

• Treatment-emergent treatment-related AEs.

• Treatment-emergent treatment-related SAEs.

• AEs leading to early discontinuation of study treatment.

• Treatment-emergent deaths.

• Cause of death.

• Treatment-emergent changes in clinical laboratory findings.

Genetic analysis

Whole genome sequencing will be performed using the Illumina Novaseq6000 platform. Genomes will be processed using an established sequencing pipeline (JLD). Briefly, sequences will be aligned to human genome reference GRCh38/hg38 and variant calling will be undertaken using GATK Haplotype caller.³¹ Variant annotation will be performed using ANNOVAR³² and standard quality control (QC) performed to remove sequence artefacts/low quality calls. Annotated telomere-associated gene sequences including promoter and 3′ regulatory sequences will be extracted. A curated gene list will include genes previously shown to harbour mutations associated with short telomeres and pulmonary fibrotic conditions in the first instance (table 1) and will be expanded to include genes associated other telomere disorders and lung fibrotic conditions.^{33 34} Single nucleotide polymorphisms (SNPs) meeting QC will be filtered as follows: population frequency <0.01% as determined using publicly available databases gnomAD (http://gnomad.broadinstitute.org/, 1000Genomes (https://www.internationalgenome.org/) and ExAC (http://exac.broadinstitute.org/), predicted pathogenicity using functional prediction tools including CADD,³⁵ MutationTaster³⁶ and other prediction tools as appropriate; ensuring inclusion of previously reported disease associated SNPs. Structural variation will also be examined.³⁷ All potentially pathogenic SNPs will be curated and evaluated using currently available databases such as VarSome³⁸ and ClinVar³⁹ and, in addition to published literature. Curated variant lists will be discussed with the TELO-SCOPE gene review panel and considered in line with current standards and guidelines for the interpretation of sequence variants (the joint consensus recommendations of the ACMG and the Association for Molecular Pathology and the ACGS Best Practice Guidelines for Variant Classification in Rare Disease 2020).⁴⁰ Agreed clinically significant genetic findings will be returned following best practice guidelines for the return of genetic results guided by CI’s clinical genetics expertise.

Table 1

Genes harbouring mutations associated with telomere disorders^{33 34}

Genes	Disease phenotype
TERT	DC, IPF/FIP, AA/MDS, familial liver cirrhosis, HHS
TERC	DC, IPF/FIP, AA/MDS, familial liver cirrhosis
DKC1	DC, HHS, IPF/FIP
RTEL1	DC, HHS, IPF/FIP
TINF2	DC, HHS, RS, IPF/FIP
PARN	IPF/FIP, DC, HHS
ZCCHC8	FIP
NAF1	IPF/FIP, CPFE
NOP10, NHP2, WRAP53, CTC1	DC
ACD	AA, DC, HHA
POT1, TPP1	BMF, CP, IPF and CLL
Genes in the Shelterin CST complexes	–
Genes: MUC5B, surfactant genes, vesicular trafficking genes	IPF

AA, aplastic anaemia; CP, coats plus; CPFE, combined pulmonary fibrosis and emphysema; DC, dyskeratosis congenita; FIP, familial interstitial pneumonia; HHS, Hoyeraal-Hreidarsson syndrome; IPF, idiopathic pulmonary fibrosis; MD, myelodysplastic syndrome; RS, Revesz syndrome.

Exploratory end-points

A pharmacogenomic study will follow the trial. After unblinding, subjects with identifiable mutations will be triaged by their response to danazol. Mutations from the top and bottom two ‘responders’ (bp/year) will be introduced into the Kucg2 iPS cell line using CRISPR-Cas9-mediated genome editing. Mutant cell lines will be assessed for telomere length by flow-FISH and terminal restriction fragment length analysis, telomerase activity by the immunoprecipitation-telomere repeat amplification protocol and human telomerase reverse transcriptase (hTERT) expression by quantitative reverse transcription PCR, prior to and during treatment (8 days) with 100 µM danazol (Sigma-Aldrich). This approach will determine whether the specific underlying mutation can explain a differential response to danazol.

Schedule of assessments

The assessment schedule is detailed in table 2. Two screening visits will occur, the first being to facilitate screening of the participant’s telomere length following informed consent. Participants meeting the inclusion criteria with no exclusions will return to complete the final screening assessments at a second visit. Trial visits will incorporate a combination of telephone and face-to-face consultations. Monitoring for known side effects of danazol will occur at all visits, including, physical examination for changes in physical features, laboratory tests for changes in liver function, coagulation profile, cholesterol and hormonal levels. A liver ultrasound is scheduled at 6 months to exclude the development of peliosis hepatis. Blood will be collected for the measurement of telomere length at baseline, 3, 6, 9 and 12 months. Questionnaires will be completed at baseline, 6 months and end of treatment. Adult participants will complete the King’s Brief Interstitial Lung Disease⁴¹ and Leicester Cough Questionnaire.⁴² In children, the parent/guardian will complete the Parent Cough Specific Quality of Life questionnaire.⁴³

Table 2

Assessment schedule

Visit

Screening

Baseline

Treatment

Follow-up

1

2

3a

3b

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

Day

−42

−42 to −1

1

2

7*

28

56

84

112*

140*

168

196*

224*

252

280*

308*

336*

364

28 days after last dose†

Telephone visit

X

X

X

X

X

X

X

X

X

Window (days)

NA

NA

NA

+1

±1

±3

±3

±3

±3

±3

±3

±3

±3

±3

±3

±3

±3

±3

±7

Informed consent

X

X

Eligibility assessments

X

X

X

Demographics, medical history

X

Physical examination, vital signs

X

X

X

X

X

X

X

X

X

Height, weight

X

X

X

X

X

ECG

X

X

X

X

X

Telomere length measurement

X‡

X§

X§

X§

X§

X§

Laboratory tests

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Pregnancy test

X

X

X

X

X

X

X

X

PFTs

X

X

X

X

Six-minute walk test

X

X

X

Questionnaires¶

X

X

X

Liver ultrasound

X

HRCT

X

X

Randomisation

X

Study drug administration

X

X

X

X

Review adherence

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Concomitant medications

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Adverse events

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

End of treatment/study form

X

X

*Phone visit.

†Follow-up visit will occur for all participants, including those terminating early; telomere length will be measured using the following notes.

‡Flow fluorescence in situ hybridisation (screening).

§Telomere shortest length assay (other visits).

¶Questionnaires include King’s Brief Interstitial Lung Disease (adults only), Leicester Cough Questionnaire (adults only) and Parent Cough-Specific Quality of Life (children only).

HRCT, high-resolution CT; NA, not applicable; PFT, pulmonary function test.

Sample size

The normal rate of telomere attrition is 60 bp/year,^{19 44} but doubles to roughly 120 bp/year in people with telomere-maintenance gene mutations. Assuming a conservative effect size (normalisation of telomere attrition) of 10% in the control group and 50% in the treated group, and assuming a power of 80% and two-sided significance level of 5%, using a 2:1 randomisation a sample size of 15 is required in the control group and 30 in the treated group, giving a total sample size of 45, with 50 enrolled to allow for a 10% drop-out rate. Analysis will be by intention-to-treat. It is estimated that the prevalence of PF associated with short telomeres is approximately 25% among undifferentiated PF patients, requiring screening of up to 200 to enrol 50 participants.

Data analysis plan

Cohort descriptive statistics, incidence of short telomeres, telomere-maintenance gene mutations and adverse events will be reported. Data will be analysed on an intention-to-treat basis using two-sided tests with p values <0.05 considered statistically significant. The primary endpoint will be assessed using two-sided test for proportions. Additional tests for secondary endpoints and rate of telomere attrition will be performed using standard parametric or non-parametric tests, controlling for confounding variables, as appropriate.

Patient and public involvement

Feedback on PF research priorities and TELO-SCOPE was obtained from the Lung Foundation Australia Pulmonary Fibrosis Consumer Advisory Group. Feedback themes were (1) lack of effective treatments; (2) access to clinical trials for regional and rural patients; (3) access to genetic counselling; (4) lack of research into genetic causes of PF; (5) impact on family members after identification of potentially heritable mutations; (6) exposure to placebo and (7) access to danazol beyond TELO-SCOPE. This feedback informed the design of TELO-SCOPE. The study protocol and participant information and consent forms underwent review by the Pulmonary Fibrosis Australasian Clinical Trials Network Consumer Advisory Group. Modifications to these documents were made following this review to address all feedback.

Data monitoring

The Data Safety and Monitoring Board (DSMB) will comprise an independent group of international experts in ILD and a statistician. A review of safety data will occur after 20 participants have completed the week 4 visit. The DSMB will report the findings to the trial steering committee, consisting of chief investigators.

Ethics and dissemination

Ethics approval has been granted in Australia by the Metro South Human Research Ethics Committee (HREC/2020/QMS/66385) and ratified by the University of Queensland (2020/HE002889). The study will be conducted and reported according to SPIRIT guidelines. Results will be published in peer-reviewed journals and presented at international and national conferences. The results will also be disseminated to patients and the public through lay publications and seminars.

Trial status

Recruitment commenced September 2021.

Ethics statements

Patient consent for publication

Not applicable.

Footnote

Contributors JM and DCC conceived the original idea for the study, drafted the funding application and led the study design. DCC is the chief investigator and has oversight for the trial. All authors contributed to protocol development and refined the trial design. STY planned the statistical analyses. All authors approve the final version of the TELO-SCOPE protocol for publication.

Funding This work was supported by National Health and Medical Research Council (Australia) Medical Research Future Fund (MRFF) grant number APP1199373. The University of Queensland is the trial sponsor.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Provenance and peer review Not commissioned; externally peer reviewed.

References

¹ Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–77. doi:10.1056/NEJMoa1113354 http://www.ncbi.nlm.nih.gov/pubmed/22607134

² Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–82. doi:10.1056/NEJMoa1402584 http://www.ncbi.nlm.nih.gov/pubmed/24836310

³ King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–92. doi:10.1056/NEJMoa1402582 http://www.ncbi.nlm.nih.gov/pubmed/24836312

⁴ Petnak T, Lertjitbanjong P, Thongprayoon C, et al. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest 2021; 160: 1751–63. doi:10.1016/j.chest.2021.06.049 http://www.ncbi.nlm.nih.gov/pubmed/34217681

⁵ Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–27. doi:10.1056/NEJMoa1908681 http://www.ncbi.nlm.nih.gov/pubmed/31566307

⁶ Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–28. doi:10.1056/NEJMoa1903076 http://www.ncbi.nlm.nih.gov/pubmed/31112379

⁷ Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8: 147–57. doi:10.1016/S2213-2600(19)30341-8 http://www.ncbi.nlm.nih.gov/pubmed/31578169

⁸ Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012; 13: 693–704. doi:10.1038/nrg3246 http://www.ncbi.nlm.nih.gov/pubmed/22965356

⁹ Armanios MY, Chen JJ-L, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317–26. doi:10.1056/NEJMoa066157 http://www.ncbi.nlm.nih.gov/pubmed/17392301

¹⁰ Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729–37. doi:10.1164/rccm.200804-550OC http://www.ncbi.nlm.nih.gov/pubmed/18635888

¹¹ Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2: 557–65. doi:10.1016/S2213-2600(14)70124-9 http://www.ncbi.nlm.nih.gov/pubmed/24948432

¹² Borie R, Tabèze L, Thabut G, et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J 2016; 48: 1721–31. doi:10.1183/13993003.02115-2015 http://www.ncbi.nlm.nih.gov/pubmed/27836952

¹³ Dai J, Cai H, Li H, et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 947–52. doi:10.1111/resp.12566 http://www.ncbi.nlm.nih.gov/pubmed/26073170

¹⁴ Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48: 1710–20. doi:10.1183/13993003.00308-2016 http://www.ncbi.nlm.nih.gov/pubmed/27540018

¹⁵ Snetselaar R, van Batenburg AA, van Oosterhout MFM, et al. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. PLoS One 2017; 12: e0189467. doi:10.1371/journal.pone.0189467 http://www.ncbi.nlm.nih.gov/pubmed/29281671

¹⁶ Newton CA, Zhang D, Oldham JM, et al. Telomere length and use of immunosuppressive medications in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200: 336–47. doi:10.1164/rccm.201809-1646OC http://www.ncbi.nlm.nih.gov/pubmed/30566847

¹⁷ Ley B, Newton CA, Arnould I, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 2017; 5: 639–47. doi:10.1016/S2213-2600(17)30216-3 http://www.ncbi.nlm.nih.gov/pubmed/28648751

¹⁸ Swaminathan AC, Neely ML, Frankel CW, et al. Lung transplant outcomes in patients with pulmonary fibrosis with Telomere-Related gene variants. Chest 2019; 156: 477–85. doi:10.1016/j.chest.2019.03.030 http://www.ncbi.nlm.nih.gov/pubmed/30978332

¹⁹ Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med 2016; 374: 1922–31. doi:10.1056/NEJMoa1515319 http://www.ncbi.nlm.nih.gov/pubmed/27192671

²⁰ Chambers DC, Lutzky VP, Apte SH, et al. Successful treatment of telomeropathy-related interstitial lung disease with immunosuppression and danazol. Respirol Case Rep 2020; 8: e00607. doi:10.1002/rcr2.607 http://www.ncbi.nlm.nih.gov/pubmed/32607243

²¹ Clé DV, Catto LF, Darrigo LG, et al. Telomere elongation and clinical improvement in Telomeropathy patients: a prospective clinical trial of nandrolone in Telomeropathies. Blood 2019; 134: 2501–01. doi:10.1182/blood-2019-130844

²² Fang C, Huang H, Zhang Q, et al. Relation between sex hormones and leucocyte telomere length in men with idiopathic pulmonary fibrosis. Respirology 2020; 25: 1265–73. doi:10.1111/resp.13871 http://www.ncbi.nlm.nih.gov/pubmed/32583532

²³ Khincha PP, Bertuch AA, Gadalla SM, et al. Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv 2018; 2: 1243–9. doi:10.1182/bloodadvances.2018016964 http://www.ncbi.nlm.nih.gov/pubmed/29853525

²⁴ Aubert G, Hills M, Lansdorp PM. Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat Res 2012; 730: 59–67. doi:10.1016/j.mrfmmm.2011.04.003 http://www.ncbi.nlm.nih.gov/pubmed/21663926

²⁵ Lai T-P, Zhang N, Noh J, et al. A method for measuring the distribution of the shortest telomeres in cells and tissues. Nat Commun 2017; 8: 1356. doi:10.1038/s41467-017-01291-z http://www.ncbi.nlm.nih.gov/pubmed/29116081

²⁶ Alder JK, Hanumanthu VS, Strong MA, et al. Diagnostic utility of telomere length testing in a hospital-based setting. Proc Natl Acad Sci U S A 2018; 115: E2358–65. doi:10.1073/pnas.1720427115 http://www.ncbi.nlm.nih.gov/pubmed/29463756

²⁷ Prasad JD, Mahar A, Bleasel J, et al. The interstitial lung disease multidisciplinary meeting: a position statement from the thoracic Society of Australia and New Zealand and the lung Foundation Australia. Respirology 2017; 22: 1459–72. doi:10.1111/resp.13163 http://www.ncbi.nlm.nih.gov/pubmed/28891101

²⁸ Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198: e44–68. doi:10.1164/rccm.201807-1255ST http://www.ncbi.nlm.nih.gov/pubmed/30168753

²⁹ Moore I, Wrobel J, Rhodes J, et al. Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulm Med 2020; 20: 257. doi:10.1186/s12890-020-01297-2 http://www.ncbi.nlm.nih.gov/pubmed/33008362

³⁰ Lai T-P, Wright WE, Shay JW. Comparison of telomere length measurement methods. Philos Trans R Soc Lond B Biol Sci 2018; 373: 20160451. doi:10.1098/rstb.2016.0451 http://www.ncbi.nlm.nih.gov/pubmed/29335378

³¹ McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–303. doi:10.1101/gr.107524.110 http://www.ncbi.nlm.nih.gov/pubmed/20644199

³² Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164. doi:10.1093/nar/gkq603 http://www.ncbi.nlm.nih.gov/pubmed/20601685

³³ Kam MLW, Nguyen TTT, Ngeow JYY. Telomere biology disorders. NPJ Genom Med 2021; 6: 36. doi:10.1038/s41525-021-00198-5 http://www.ncbi.nlm.nih.gov/pubmed/34050178

³⁴ Aramburu T, Plucinsky S, Skordalakes E. POT1-TPP1 telomere length regulation and disease. Comput Struct Biotechnol J 2020; 18: 1939–46. doi:10.1016/j.csbj.2020.06.040 http://www.ncbi.nlm.nih.gov/pubmed/32774788

³⁵ Rentzsch P, Witten D, Cooper GM, et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 2019; 47: D886–94. doi:10.1093/nar/gky1016 http://www.ncbi.nlm.nih.gov/pubmed/30371827

³⁶ Steinhaus R, Proft S, Schuelke M, et al. MutationTaster2021. Nucleic Acids Res 2021; 49: W446–51. doi:10.1093/nar/gkab266 http://www.ncbi.nlm.nih.gov/pubmed/33893808

³⁷ Layer RM, Chiang C, Quinlan AR, et al. LUMPY: a probabilistic framework for structural variant discovery. Genome Biol 2014; 15: R84. doi:10.1186/gb-2014-15-6-r84 http://www.ncbi.nlm.nih.gov/pubmed/24970577

³⁸ Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics 2019; 35: 1978–80. doi:10.1093/bioinformatics/bty897 http://www.ncbi.nlm.nih.gov/pubmed/30376034

³⁹ Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018; 46: D1062–7. doi:10.1093/nar/gkx1153 http://www.ncbi.nlm.nih.gov/pubmed/29165669

⁴⁰ Ellard S, Baple EL, Callaway A. ACGS best practice guidelines for variant classification in rare disease 2020, 2020. Available: https://www.acgs.uk.com/media/11631/uk-practice-guidelines-for-variant-classification-v4-01-2020.pdf

⁴¹ Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King"s brief interstitial lung disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804–10. doi:10.1136/thoraxjnl-2012-201581 http://www.ncbi.nlm.nih.gov/pubmed/22555278

⁴² Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester cough questionnaire (LCQ). Thorax 2003; 58: 339–43. doi:10.1136/thorax.58.4.339 http://www.ncbi.nlm.nih.gov/pubmed/12668799

⁴³ Newcombe PA, Sheffield JK, Juniper EF, et al. Development of a parent-proxy quality-of-life chronic cough-specific questionnaire: clinical impact vs psychometric evaluations. Chest 2008; 133: 386–95. doi:10.1378/chest.07-0888 http://www.ncbi.nlm.nih.gov/pubmed/18252913

⁴⁴ Alter BP, Rosenberg PS, Giri N, et al. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica 2012; 97: 353–9. doi:10.3324/haematol.2011.055269 http://www.ncbi.nlm.nih.gov/pubmed/22058220